+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of LY4268989 compared to a placebo in adults with moderately to severely active ulcerative colitis UC. The study involves participants aged 18 to 80 who have had UC for at least three months and have active symptoms confirmed by specific scoring methods. This Phase 2 clinical trial is sponsored by Eli Lilly and Company and focuses on treatment effects over a long period. Participants will receive oral doses of LY4268989 or a matching placebo in a randomized, double-blind design. The study includes two experimental dose groups of LY4268989 and one placebo group. Treatment and evaluation will continue for up to approximately 108 weeks, excluding the screening period. During the trial, participants will be regularly assessed for clinical remission and response using the Modified Mayo Score at weeks 10 and 52. Researchers will monitor symptomatic responses and drug levels in the blood up to week 52. Safety and effectiveness data will be collected throughout the study, with the overall duration lasting up to about two years.

Age: 18Years - 80YearsAll GendersPhase 2
258 locations
O

Actively Recruiting

Healthy Volunteer

Researchers are investigating the link between preoperative cognitive impairment and postoperative delirium POD in adults aged 65 and older undergoing elective total hip arthroplasty in the Czech Republic. Postoperative delirium is a common and serious complication associated with higher risks of illness, death, longer hospital stays, and lasting cognitive and functional decline. Despite recommendations, regular cognitive screening before surgery is not widely practiced. This observational study uses the ALBA test, a brief cognitive screening tool performed during the pre-anesthetic assessment, to predict the risk of POD, which will be assessed using the CAM-ICU tool for up to 72 hours after surgery. The study also examines how frailty, multiple medications, other health conditions, type of anesthesia, blood loss, medication during surgery, and postoperative complications relate to delirium. About 300-400 participants will be enrolled across seven centers, with no additional tests or changes to their standard care. Participants will undergo routine clinical care with cognitive screening before surgery and delirium monitoring after surgery. Data will be collected in an electronic system and analyzed to evaluate how well the ALBA test predicts delirium and to explore how feasible it is to include this screening in regular practice. The main outcome is the incidence of delirium within 72 hours after surgery, along with multiple secondary measures such as frailty, medication use, anemia, anesthesia type, and postoperative events. The study aims to improve preoperative evaluation and patient outcomes without adding extra procedures or biological sampling.

Age: 65Years +All Genders
7 locations